The Diagnostic Value of Circulating VEGF in Diabetic Retinopathy in Asia: A Systematic Review and Meta-analysis

Ophthalmic Epidemiol. 2023 Jun;30(3):230-238. doi: 10.1080/09286586.2022.2088805. Epub 2022 Jul 7.

Abstract

Purpose: Vascular endothelial growth factor (VEGF) has obvious clinical value in diabetes, but the conclusions on the diagnostic value of diabetic retinopathy (DR) are not consistent. This study aims to comprehensively evaluate the accuracy of circulating VEGF in the diagnosis of DR in the Asian population by a method of meta-analysis.

Methods: PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and China Wanfang Databases were searched for relevant studies on the diagnostic value of VEGF for DR in Asia up to November 2021. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and areas under the curve (AUC) were calculated by Stata 15.0 software.

Results: After screening, eight eligible studies were enrolled, including 547 patients with DR. The results of the meta-analysis showed that the pooled DOR, sensitivity, specificity, PLR, and NLR were 31.67 (95%CI: 13.55 ~ 74.05), 0.86 (95%CI: 0.74 ~ 0.93), 0.84 (95%CI: 0.80 ~ 0.87), 5.33 (95%CI: 4.09 ~ 6.93), 0.17 (95%CI: 0.09 ~ 0.32), respectively. The AUC was 0.86 (95%CI: 0.82 ~ 0.89).

Conclusion: Circulating VEGF has a good diagnostic value in DR in the Asian population, with the potential to be an early diagnostic marker for DR.

Keywords: VEGF; diabetic retinopathy; diagnostic value; meta-analysis.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • Asia
  • Asian People
  • Diabetes Mellitus*
  • Diabetic Retinopathy*
  • Humans
  • Sensitivity and Specificity
  • Vascular Endothelial Growth Factor A

Substances

  • Vascular Endothelial Growth Factor A